they keep on referencing RP11 as a ‘co-lead’ ; reading it simply as a layman (which I am) I’m assuming ADOA has been worked up to a point where it’s ‘ready’? Maybe they’ve been working up ADOA through GLP/PK in stealth and its IND ready? (Just trying to make sense of the delays to date)
I think the team here is already fully informed, but there’s a lot for other shareholders/market to catch up on: 1) GLP status 2) PK relevance 3) Patent expansion/Pipeline beyond the co-leads: CNS, Kidney, Neurodegenerative
PYC Price at posting:
7.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)